Innate Pharma Announces Transformative Strategy to Accelerate Growth
Innate Pharma (Nasdaq: IPHA) announced a new growth strategy based on three key pillars: driving innovation with their proprietary ANKET® NK-cell engager Platform, accelerating development of Antibody-Drug Conjugates (ADCs), and advancing late-stage assets through partnerships.
The company is developing IPH6501, an ANKET® therapy currently in Phase 1/2 study for CD20-expressing non-Hodgkin's Lymphoma, and IPH4502, a topoisomerase I inhibitor ADC targeting Nectin-4 in Phase 1 trials for advanced solid tumors.
For late-stage assets, Innate is seeking partners for lacutamab in advanced T cell lymphomas, while monalizumab, partnered with AstraZeneca, is in Phase 3 PACIFIC-9 trial for non-small cell lung cancer with readouts expected by end of 2026.
Innate Pharma (Nasdaq: IPHA) ha annunciato una nuova strategia di crescita basata su tre pilastri chiave: promuovere l'innovazione con la loro piattaforma proprietaria ANKET® NK-cell engager, accelerare lo sviluppo degli Antibody-Drug Conjugates (ADC) e far avanzare le risorse in fase avanzata attraverso partnership.
La compagnia sta sviluppando IPH6501, una terapia ANKET® attualmente in studio di Fase 1/2 per il linfoma non-Hodgkin a espressione di CD20, e IPH4502, un inibitore della topoisomerasi I ADC mirato a Nectin-4 in studi di Fase 1 per tumori solidi avanzati.
Per le risorse in fase avanzata, Innate sta cercando partner per il lacutamab nei linfomi T avanzati, mentre il monalizumab, in partnership con AstraZeneca, è in fase 3 dello studio PACIFIC-9 per il cancro polmonare non a piccole cellule con risultati attesi entro la fine del 2026.
Innate Pharma (Nasdaq: IPHA) anunció una nueva estrategia de crecimiento basada en tres pilares clave: impulsar la innovación con su plataforma propietaria de ANKET® NK-cell engager, acelerar el desarrollo de los Antibody-Drug Conjugates (ADCs) y avanzar en los activos de última etapa a través de alianzas.
La compañía está desarrollando IPH6501, una terapia ANKET® actualmente en estudio de Fase 1/2 para linfoma no Hodgkin que expresa CD20, y IPH4502, un ADC inhibidor de la topoisomerasa I dirigido a Nectin-4 en ensayos de Fase 1 para tumores sólidos avanzados.
Para los activos de última etapa, Innate está buscando socios para el lacutamab en linfomas T avanzados, mientras que el monalizumab, asociado con AstraZeneca, está en el ensayo PACIFIC-9 en fase 3 para cáncer de pulmón no microcítico, con resultados esperados para finales de 2026.
Innate Pharma (Nasdaq: IPHA)는 세 가지 핵심 기둥을 기반으로 한 새로운 성장 전략을 발표했습니다: 자사의 고유한 ANKET® NK-cell engager 플랫폼을 통한 혁신 추진, 항체-약물 접합체 (ADC) 개발 가속화, 및 파트너십을 통한 후기 단계 자산 개발입니다.
회사는 현재 CD20을 발현하는 비호지킨 림프종에 대해 1/2상 연구 중인 ANKET® 요법인 IPH6501과, 고형 종양 치료를 위한 1상 시험 중 Nectin-4에 목표로 하는 토포이소머라제 I 억제제 ADC인 IPH4502를 개발하고 있습니다.
후기 단계 자산을 위해 Innate는 고급 T 세포 림프종에 대한 lacutamab의 파트너를 찾고 있으며, 아스트라제네카와 파트너 관계를 맺은 monalizumab은 비소세포 폐암에 대한 3상 PACIFIC-9 시험에 있으며, 결과는 2026년 말까지 기대됩니다.
Innate Pharma (Nasdaq: IPHA) a annoncé une nouvelle stratégie de croissance basée sur trois piliers clés : promouvoir l'innovation avec leur plateforme propriétaire ANKET® NK-cell engager, accélérer le développement des conjugués anticorps-médicaments (ADC) et faire avancer les actifs en phase avancée grâce à des partenariats.
L'entreprise développe IPH6501, une thérapie ANKET® actuellement en étude de phase 1/2 pour le lymphome non-Hodgkin exprimant le CD20, et IPH4502, un inhibiteur de la topoisomérase I ADC ciblant Nectin-4 en essais de phase 1 pour les tumeurs solides avancées.
Pour les actifs en phase avancée, Innate recherche des partenaires pour le lacutamab dans les lymphomes T avancés, tandis que le monalizumab, en partenariat avec AstraZeneca, est en essai de phase 3 PACIFIC-9 pour le cancer du poumon non à petites cellules, avec des résultats attendus d'ici la fin de 2026.
Innate Pharma (Nasdaq: IPHA) hat eine neue Wachstumsstrategie angekündigt, die auf drei Schlüsselstützen basiert: Innovation mit ihrer proprietären ANKET® NK-cell engager-Plattform vorantreiben, die Entwicklung von Antikörper-Arzneimittel-Konjugaten (ADCs) beschleunigen und späte Vermögenswerte durch Partnerschaften voranbringen.
Das Unternehmen entwickelt IPH6501, eine ANKET®-Therapie, die derzeit in einer Phase-1/2-Studie für CD20-exprimierenden non-Hodgkin-Lymphom untersucht wird, und IPH4502, einen Topoisomerase-I-Inhibitor-ADC, der in Phase-1-Studien auf Nectin-4 für fortgeschrittene solide Tumoren abzielt.
Für späte Vermögenswerte sucht Innate Partner für Lacutamab bei fortgeschrittenen T-Zell-Lymphomen, während Monalizumab, das mit AstraZeneca kooperiert, sich in der Phase-3 PACIFIC-9-Studie für nicht-kleinzelliges Lungenkarzinom befindet, mit Ergebnissen, die bis Ende 2026 erwartet werden.
- ANKET® platform shows potential applications in multiple areas: hematologic malignancies, solid tumors, and autoimmune diseases
- Two clinical-stage assets in development: IPH6501 (Phase 1/2) and IPH4502 (Phase 1)
- Strategic partnership with AstraZeneca for monalizumab in Phase 3 trial
- Seeking partnership for lacutamab indicates possible resource constraints for independent development
- Phase 3 trial results for monalizumab not expected until end of 2026
Insights
The strategic pivot towards early clinical development of proprietary assets marks a important evolution for Innate Pharma. The ANKET® NK-cell engager platform represents a significant technological advantage in the competitive immunotherapy landscape, particularly given its dual capability to engage and proliferate NK cells - a unique feature not commonly found in competitor platforms.
The company's ADC program, led by IPH4502, is particularly noteworthy as it targets Nectin-4, an increasingly validated target in oncology. The use of exatecan as a payload differentiates it from current market leaders, potentially offering an improved therapeutic window. The Phase 1 trial initiation timing aligns well with the growing ADC market momentum.
The partnership strategy for late-stage assets, especially the PACIFIC-9 Phase 3 trial with AstraZeneca, provides a de-risked approach to value creation. The 2026 readout timeline for monalizumab offers a clear catalyst for medium-term value realization.
This strategic realignment significantly strengthens Innate Pharma's market position and financial outlook. The focus on proprietary early-stage assets, particularly the ANKET® platform, could substantially increase the company's negotiating leverage for future partnerships and licensing deals. The
The dual-track approach of advancing both NK cell engagers and ADCs diversifies development risk while maintaining focus in high-value oncology segments. The partnership model for late-stage assets optimizes capital allocation, allowing the company to maximize returns on early-stage investments while maintaining upside exposure to advanced programs through milestone payments and royalties.
-
Strategy anchored on early clinical development of proprietary assets with single-agent potential:
- Drive innovation with first-in-class ANKET® NK-cell engager Platform
- Accelerate development of differentiated Antibody-Drug Conjugates
- Advance current late-stage assets through partnerships
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced its updated strategy for company growth. This comprehensive plan is anchored in three key pillars designed to drive sustainable growth, foster innovation, and deliver transformative therapies to patients worldwide.
"Our updated strategy underscores Innate Pharma’s unwavering dedication to innovation, collaboration, and delivering transformative therapies for patients worldwide," said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. "With a focus on our ANKET® platform and ADC programs, we are poised to redefine the landscape of immunotherapy, addressing unmet needs in oncology and autoimmune diseases. This roadmap reflects our steadfast commitment to advancing science, strengthening partnerships, and maximizing value for patients and shareholders alike as we look toward a brighter future in immuno-oncology."
Jonathan Dickinson will represent the Company in a session at the 43rd Annual J.P. Morgan Healthcare Conference scheduled Tuesday, January 14, 2025 from 11:15 - 11:55 am PST. |
|
A live webcast of the session will be available at the following link:
|
|
Three Pillars of Growth
- Drive innovation with first-in-class ANKET® Platform: A new era in NK cell therapeutics is at the heart of Innate Pharma’s strategy, based around its validated, proprietary Antibody-based NK Cell Engager Therapeutics (ANKET®) platform. This cutting-edge technology with anticipated applications in hematologic malignancies, solid tumors, and autoimmune diseases leverages the advantages of harnessing NK cell effector functions and can create proliferation of NK cells. By advancing its clinical pipeline, Innate aims to exploit therapeutic possibilities in oncology and autoimmune diseases. IPH6501, Innate’s proprietary ANKET® is currently being investigated in a Phase 1/2 study in patients with CD20-expressing non-Hodgkin’s Lymphoma.
- Accelerate development of differentiated Antibody-Drug Conjugates (ADCs): Innate Pharma is advancing its ADC programs to develop differentiated and highly targeted treatments that combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs. IPH4502, Innate’s lead ADC, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4, is being investigated in a Phase 1 trial in patients with advanced solid tumors.
- Advance current late-stage assets through partnerships: Partnerships will continue to play a critical role in the Company’s strategy, for broader impact with Innate’s established antibody assets, including lacutamab and monalizumab. Innate is actively seeking a partner to progress lacutamab for patients with advanced forms of T cell lymphomas. Monalizumab, currently in a Phase 3 trial PACIFIC-9 led by AstraZeneca in non-small cell lung cancer, will see readouts by end of 2026. By entrusting these promising therapies to strategic partners, Innate ensures their ongoing development and potential commercialization, maximizing their therapeutic potential and reach.
With this multi-faceted strategy, Innate Pharma believes it is positioned to accelerate its growth trajectory and reinforce its leadership in the immuno-oncology space. The Company’s robust scientific expertise, strategic collaborations, and focus on patient outcomes create a strong foundation for success.
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET® (Antibody-based NK cell Engager Therapeutics) proprietary platform and Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs).
Innate’s portfolio includes several ANKET® drug candidates to address multiple tumor types as well as IPH4502 a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with AstraZeneca in non-small cell lung cancer.
Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.
Headquartered in
Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.
Information about Innate Pharma shares
ISIN code
|
FR0010331421 Euronext: IPH Nasdaq: IPHA 9695002Y8420ZB8HJE29 |
Disclaimer on forward-looking information and risk factors
This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “may,” “might,” “potential,” “expect” “should,” “will,” or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s reliance on third parties to manufacture its product candidates, the Company’s commercialization efforts and the Company’s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the
In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250109242503/en/
For additional information, please contact:
Investors
Innate Pharma
Henry Wheeler
Tel.: +33 (0)4 84 90 32 88
Henry.wheeler@innate-pharma.fr
Media Relations
NewCap
Arthur Rouillé
Tel.: +33 (0)1 44 71 00 15
innate@newcap.eu
Source: Innate Pharma SA
FAQ
What are the three pillars of Innate Pharma's (IPHA) new growth strategy?
What is the current development status of IPH6501 for IPHA?
When are the Phase 3 PACIFIC-9 trial results for IPHA's monalizumab expected?
What is the development stage of IPHA's IPH4502 ADC program?
Which late-stage asset is IPHA seeking to partner?
